KISSH Serum Antibody Test Kit LTIA Covid 19 Antibody Fast Detection Kit

SARS-CoV-2 Antibodies Detection Kit (Latex particle-enhanced turbidimetric immunoassay)

Product information

Product Description

SARS-CoV-2 Antibodies Test Kit(Latex particle-enhanced turbidimetric immunoassay) is intended for qualitative and semi-quantitative detection of antibodies to SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum .

SARS-CoV-2, the causative agent of Coronavirus Disease 2019 (COVID-19), is an enveloped, single-stranded RNA Betacoronavirus. 7 coronaviruses have been identified as agents of human infection, causing disease ranging from mild common cold to severe respiratory failure.

SARS-CoV-2 is transmitted primarily from person-to-person through respiratory droplets and aerosols. The incubation period from infection to detectable viral load in the host commonly ranges from 2 to 14 days. Detection of viral load can be associated with the onset of clinical signs and symptoms, although a considerable proportion of individuals remains asymptomatic or mildly symptomatic. The interval during which an individual with COVID-19 is infectious has not yet been clearly established, however, transmission from symptomatic, asymptomatic, and pre-symptomatic individuals has been well described. Coronavirus genomes encode 4 main structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N). The S protein is a very large transmembrane protein that assembles into trimers to form the distinctive surface spikes of coronaviruses. Each S monomer consists of an N-terminal S1 domain and a membrane-proximal S2 domain. The virus gains entry to the host cell through binding of the S protein to the angiotensin-converting enzyme 2 (ACE2), which is enzymatically active on the surface of numerous cell types including the alveolar type II cells of the lung and epithelial cells of the oral mucosa. Mechanistically, ACE2 is engaged by the receptor-binding domain (RBD) on the S1 subunit.

Upon infection with SARS-CoV-2, the host mounts an immune response against the virus, typically including production of specific antibodies against viral antigens. IgM and IgG antibodies to SARS-CoV-2 appear to arise nearly simultaneously in blood.There is significant inter-individual difference in the levels and chronological appearance of antibodies in COVID-19 patients, but median seroconversion has been observed at approximately 2 weeks.

Serologic assays can play an important role in understanding viral epidemiology in the general population. The SARS-CoV-2 Antibodies Test Kit(Latex particle-enhanced turbidimetric immunoassay) uses a recombinant protein representing the RBD of the S antigen .